PubRank
Search
About
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
Clinical Trial ID NCT00621452
PubWeight™ 17.26
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT00621452
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Blood
2010
3.57
2
The basic principles of chimeric antigen receptor design.
Cancer Discov
2013
3.28
3
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood
2012
2.97
4
Gene-engineered T cells for cancer therapy.
Nat Rev Cancer
2013
2.07
5
Driving CAR T-cells forward.
Nat Rev Clin Oncol
2016
1.09
6
Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells.
Discov Med
2010
0.99
7
Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells.
Front Immunol
2013
0.98
8
Genetically engineered T cells for the treatment of cancer.
J Intern Med
2013
0.83
9
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
10
Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.
Immunotargets Ther
2015
0.75
11
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.
Pediatr Blood Cancer
2015
0.75
Next 100